Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate.
Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate.
复制标题
良性肥大和前列腺癌患者血浆和前列腺组织中的雄激素水平。
作者：
F. Habib;I. R. Lee;S. R. Stitch;P. Smith
用放射免疫法测定了10例良性前列腺增生症(BPH)和10例前列腺癌患者血浆和前列腺组织中睾酮、双氢睾酮和雄烯二酮的浓度。结果表明，BPH患者外周血睾酮、DHT和雄烯二酮水平[19.7+/-2.6，2.6+/-0.9和5.5+/-1.7(S.E.M.)]无显著差异。癌组织分别为16.9+/-2.8、2.4+/-0.5、4.4+/-1.1nmol/L(P均大于0.1)。而前列腺癌组织中DHT：睾酮(3.59+/-0.55，BPH为3.59+/-0.55，癌为0.66+/-0.09)和雄烯二酮：睾酮(2.83+/-0.38，癌为1.07+/-0.16)比值明显低于良性肥大(均P<0.01)。因此，相对于BPH组织中发现的值，癌中睾酮的积累与血浆中雄激素浓度的变化无关，但可能与局部因素和前列腺内的新陈代谢变化有关。
Specific radioimmunoassays for testosterone, dihydrotestosterone (DHT) and androstenedione were carried out to measure the concentrations of the three hormones in the plasma and prostatic tissue of ten patients with benign prostatic hypertrophy (BPH) and ten patients with carcinoma of the prostate. The results indicate that there are no significant differences between the peripheral plasma concentrations of testosterone, DHT and androstenedione in BPH [19.7 +/- 2.6, 2.6 +/- 0.9 AND 5.5 +/- 1.7 (S.E.M.) nmol/l respectively] and in carcinoma [16.9 +/- 2.8, 2.4 +/- 0.5, 4.4 +/- 1.1 nmol/l respectively], (in all cases P greater than 0.1). In contrast, the prostate tissue rations DHT: testosterone (3.59 +/- 0.55 for BPH and 0.66 +/- 0.09 for carcinoma) and androstenedione: testosterone (2.83 +/- 0.38 for BPH and 1.07 +/- 0.16 for carcinoma) are significantly less in carcinoma than in benign hypertrophy ( in all cases P less than 0.01). The accumulation of testosterone in the carcinoma, relative to values found in BPH tissue is, therefore, not associated with changes in the concentrations of androgens in the plasma pool but may be related to local factors and metabolic changes within the prostate.